<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03008980</url>
  </required_header>
  <id_info>
    <org_study_id>CDx 103</org_study_id>
    <nct_id>NCT03008980</nct_id>
  </id_info>
  <brief_title>WATS3D for the Detection of Esophageal Dysplasia</brief_title>
  <official_title>Wide Area Transepithelial Sample Esophageal Biopsy Combined With Computer Assisted 3-Dimensional Analysis (WATS) for the Detection of Esophageal Dysplasia: A Prospective, Randomized, Tandem Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CDx Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rockford Gastroenterology Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CDx Diagnostics</source>
  <brief_summary>
    <textblock>
      Patients will be recruited from participating institutions prior to planned routine care EGD&#xD;
      with WATS3D brush samples and forceps biopsies. Eligibility will be reviewed and patients who&#xD;
      are potentially eligible for the study will be approached regarding the study. If interested,&#xD;
      participants will be consented and proceed with routine care EGD. The study coordinator or&#xD;
      other research personnel will document information from the routine care endoscopy as part of&#xD;
      this research study. Follow-up information collected will include WATS3D cytology and forceps&#xD;
      biopsy pathology results from any routine care endoscopy performed during the course of&#xD;
      participation in the study, any surgeries received and related to their condition, and any&#xD;
      other care received as part of their condition. WATS3D samples will be sent to CDx&#xD;
      Diagnostics for analysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Outcomes of patients undergoing WATS sampling. Specifically incremental yield for Barrett's Esophagus and Esophageal Dysplasia due to WATS sampling above that noted from routine forceps biopsies in various clinical settings.</measure>
    <time_frame>up to 18 years</time_frame>
  </primary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Actual">160</enrollment>
  <condition>Barrett Esophagus</condition>
  <condition>Esophageal Dysplasia</condition>
  <condition>Esophagus Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Community GI Group</arm_group_label>
    <description>Diagnostic Test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Academic GI Group</arm_group_label>
    <description>Diagnostic Test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Academic Esophageal Dysplasia and Cancer</arm_group_label>
    <description>Diagnostic Test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Community Barrett's Esophagus Screening</arm_group_label>
    <description>Diagnostic Test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Community Esophageal Dysplasia</arm_group_label>
    <description>Diagnostic Test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-Ablation BE and Esophagus Dysplasia</arm_group_label>
    <description>Diagnostic Test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GERD, BE, and Esophageal Dysplasia</arm_group_label>
    <description>Diagnostic Test</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diagnostic Test</intervention_name>
    <arm_group_label>Academic Esophageal Dysplasia and Cancer</arm_group_label>
    <arm_group_label>Academic GI Group</arm_group_label>
    <arm_group_label>Community Barrett's Esophagus Screening</arm_group_label>
    <arm_group_label>Community Esophageal Dysplasia</arm_group_label>
    <arm_group_label>Community GI Group</arm_group_label>
    <arm_group_label>GERD, BE, and Esophageal Dysplasia</arm_group_label>
    <arm_group_label>Post-Ablation BE and Esophagus Dysplasia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with known Barrett's Esophagus.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients age: â‰¥ 18 years&#xD;
&#xD;
          -  Patients should have a history of Barrett's esophagus (with or without dysplasia of&#xD;
             either indefinite, low grade or high-grade)&#xD;
&#xD;
          -  Willingness to undergo both WATS and forceps biopsies while undergoing conventional&#xD;
             EGD with sedation&#xD;
&#xD;
          -  Ability to provide written, informed consent (approved by IRB) and understand the&#xD;
             responsibilities of trial participation&#xD;
&#xD;
          -  Only patients who undergo both forceps biopsies and WATS of the esophagus will be&#xD;
             included in this study&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Coagulopathy with an international normalized ratio above 2.0;&#xD;
&#xD;
          -  Thrombocytopenia with platelet counts below 50,000&#xD;
&#xD;
          -  History of prior esophageal ablation therapies, esophageal or gastric surgery&#xD;
&#xD;
          -  Unresolved drug or alcohol dependency&#xD;
&#xD;
          -  Pregnancy or planned pregnancy during the study period&#xD;
&#xD;
          -  Patients found to have a BE length less than 1 cm or greater than 10 cm&#xD;
&#xD;
          -  Patients with any visible lesions greater than 10 mm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mike Smith</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 23, 2016</study_first_submitted>
  <study_first_submitted_qc>December 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2017</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

